Microenvironment and Immunity of Digestive Cancers - East Paris Multicentric Cohort

Interactions Between Tumor, Tumor Microenvironment and Immune System in Digestive Cancers : Impact on Survival and Response to Treatment

Status

Not yet recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04707365

Acronym

MICADO

Enrollment

200

Registered

2021-01-13

Start date

2021-03-31

Completion date

2035-03-31

Last updated

2021-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary Tract Tumor, Colorectal Cancer, Immune System and Related Disorders, Pancreas Tumor

Brief summary

Colorectal and pancreatobiliary cancers are the most common digestive cancers. Their incidence has particularly increased over the last few decades, leading to suspicion that environmental factors are involved. In addition, strategies for the therapeutic management of these cancers are evolving in the context of the development of immunotherapies. Tumor microenvironment is a potential source of new diagnostic, prognostic and predictive markers and new therapeutic targets. The links between tumor microenvironment and modulation of the immune system in colorectal and pancreatobiliary cancers are poorly understood. Molecular classifications have been proposed for these cancers, but their link with immunity and response to treatment remains to be explored. Objective : explore links between molecular subtypes, tumor microenvironment, host (immune system, pre-metastatic niche, intestinal microbiota, metabolism), and survival (prognostic value), response (predictive value) and tolerance (toxicities) to treatments in digestive cancers, in particular colorectal and pancreatobiliary cancers. Method: Retrospective and prospective monocentric cohort study

Interventions

BIOLOGICALTumor samples

for each patient: liver sampling, blood samples ( serum, plasma, PBMC, whole blood), per-endoscopic bile sampling, stool samples, and materials derived from fresh tumors

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Intervention model description

Retrospective and prospective monocentric cohort study

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Colorectal or pancreatic adenocarcinoma or biliary tract adenocarcinoma * Cytologically or histologically proven adenocarcinoma, regardless of stage and treatment * Age ≥ 18 years old * Diagnosed from 2015 onwards * Signed Consent * Affiliation to a social security scheme (including CMU (Universal health coverage))

Exclusion criteria

* Patient under guardianship, curatorship or safeguarding of justice * Pregnant or breastfeeding woman * Any medical, psychological or social situation that could prevent compliance with the protocol according to the investigator's assessment. * Refusal to participate in the study * Patient on AME (state medical assistance) * Persons deprived of liberty by a judicial or administrative decision * Persons under psychiatric care

Design outcomes

Primary

Measure	Time frame	Description
overall survival	observation from first cancer treatment date until date of death or 10 years follow up if patient alive	Overall survival (OS): vital status (alive/deceased)

Contacts

Primary ContactChristophe Tournigand, MD-PHD

christophe.tournigand@aphp.fr0149812567

Backup ContactIlaria Cascone, PHD

ilaria.cascone@u-pec.fr0149813765

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026